— Published date: 1/14/2026
Value Proposition: Fusion protein that can be used to prevent and treat arthritogenic alphavirus infections.
Technology Description
Researchers at Washington University in St. Louis have identified MXRA8 (matrix remodeling associated protein 8) protein as a key recepto…
— Published date: 1/14/2026
Value Proposition: Novel target for therapeutic treatment of obesity and related metabolic diseases.
Technology Description
Researchers at Washington University in St. Louis have developed a therapeutic targeting MXRA8 to treat obesity and associated metabolic disea…
— Published Date: 12/20/2024
Value Proposition: Treats brain tumors by combining a hematopoietic growth protein and cancer therapeutics to increase survival rates.
Technology Description
Researchers at Washington University in St. Louis have developed a new way to treat brain cancers by combining…
— T-017429 Engineered Oncolytic Zika Virus Therapy for Glioblastoma
Technology Description
Researchers in the laboratories of Michael Diamond and Milan Chheda at Washington University have developed prospective treatments for glioblastoma (GBM) through the application of an engineered Zika virus (ZI…
— Disease indication – SARS-CoV-2 infection (COVID-19)
Drug format – Chimeric monoclonal antibody
Drug class – Best-in-class
Research stage and Preliminary data – The inventors have developed and characterized this antibody, creating a chimeric version with a human IgG backbone. T…
— Mayaro virus (MAYV) is an emerging mosquito-transmitted alphavirus. This is a panel of 18 neutralizing mAbs agains MAYV, 11 of which have activity that inhibited infection with EC50 values <10ng/ml. Earnest, J. T., Basore, K., Roy, V., Bailey, A. L., Wang, D., Alter, G., ... & Diamond, M. S.…
| Name | # Summaries | Author |
|---|---|---|
| 15 | ||
| 13 | ||
| 15 | ||
| 26 | ||
| 14 | ||
| 14 |
Creating...
